Brief: LIDDS Licensee Evaluates Novel Expeditated Regulatory Path For Liproca Depot In China
20/08/2020 07:51
Aug 20 (Reuters) - Lidds AB LIDDS.ST :
* REG-LIDDS LICENSEE, PUHENG PHARMA, EVALUATES A NOVEL
EXPEDITATED
REGULATORY PATH FOR LIPROCA DEPOT IN CHINA
* FINAL DATA FROM LPC-004 STUDY CONFIRMED LIPROCA® DEPOT'S
POTENTIAL AS AN ANTI-ANDROGEN TREATMENT FOR PROSTATE CANCER
PATIENTS THAT ARE CURRENTLY UNDER 'ACTIVE SURVEILLANCE'
* STUDY MET BOTH PRIMARY AND SECONDARY ENDPOINTS
Source text for Eikon: ID:nGNE4y7pxB
Further company coverage: LIDDS.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Lidds AB
See all newsBrief: Liquidator To Apply For Lidds To Be Declared Bankrupt
Brief: Lidds To Delist Shares From Nasdaq First North
Brief: Lidds Proposes Voluntary Liquidation And Delisting
Brief: Lidds Decides To Terminate Process Regarding Reverse Acquisition Of Proport Invest
Brief: Lidds Signs Agreement For Reverse Takeover Of Proport Invest